Akeso's Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Combination Therapy for PD-(L)1 Resistant NSCLC Showcased in Oral Presentation at 2024 Asian ...
HONG KONG , Dec. 4, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the results from a prospective, open-label, single-arm, multi-center phase Ib/II clinical study (...
Loews Arlington Selects ROH to Streamline Sales Operations and Payment Processing
NEW YORK--(BUSINESS WIRE)-- #SaaS--ROH, the hospitality industry's first payments and revenue management platform designed to help hotels increase profitability, today announced that Loews Arlingto...
FDA approves Roche's Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy
Basel, 13 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq HybrezaTM (atezolizumab and hyaluronidase-tqjs)...
FDA Approves Genentech's Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tece...
LOEWS CORPORATION ANNOUNCES QUARTERLY DIVIDEND ON COMMON STOCK
NEW YORK , Aug. 6, 2024 /PRNewswire/ -- Loews Corporation (NYSE: L) announced today the declaration of the Company's quarterly dividend of $0.0625 per share of Common Stock, payable September 3, 20...
Loews reports strong 3Q earnings, supported by insurance operations
Loews (NYSE:L) has reported a strong recovery in third-quarter revenue and earnings, supported by its insurance business and higher investment income. The conglomerate grew revenue to $3.93 billion...
Related Companies